Prudential Financial
RXRX icon

Prudential Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Prudential Financial’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Buy
82,850
+12,190
+17% +$40.6K ﹤0.01% 2097
2026
Q1 		$217K Buy
70,660
+47,580
+206% +$184K ﹤0.01% 2116
2025
Q4 		$94.4K Sell
23,080
-22,565
-49% -$112K ﹤0.01% 2121
2025
Q3 		$223K Buy
45,645
+2,575
+6% +$13.5K ﹤0.01% 2189
2025
Q2 		$218K Buy
43,070
+24,280
+129% +$119K ﹤0.01% 2181
2025
Q1 		$99.4K Buy
18,790
+2,720
+17% +$19.8K ﹤0.01% 2131
2024
Q4 		$109K Hold
16,070
– – ﹤0.01% 2141
2024
Q3 		$106K Sell
16,070
-18,415
-53% -$132K ﹤0.01% 2571
2024
Q2 		$259K Buy
34,485
+1,515
+5% +$13.2K ﹤0.01% 2406
2024
Q1 		$329K Buy
+32,970
New +$367K ﹤0.01% 2307

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Prudential Financial's RXRX Position: Q2 2026 in Review

Prudential Financial increased its Recursion Pharmaceuticals (RXRX) stake by 17% in Q2 2026, buying an estimated $40.6K and bringing the position to 82,850 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #2097.

Prudential Financial first reported a position in RXRX in Q1 2024 and has held it in 10 quarters since. The position peaked at $329K in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Prudential Financial held 82,850 shares of Recursion Pharmaceuticals worth $304K as of Q2 2026.
  • Prudential Financial bought 12,190 Recursion Pharmaceuticals shares in Q2 2026, an estimated $40.6K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2097 holding.
  • Prudential Financial first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Prudential Financial's Recursion Pharmaceuticals position peaked at $329K in Q1 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.